Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||Bicalutamide + HSV-Tk + Leuprolide + Valacyclovir|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Bicalutamide||Casodex||Hormone - Anti-androgens 27||Casodex (bicalutamide) is an androgen-receptor antagonist that binds androgen receptors and inhibits androgen binding, therefore inhibits AR-dependent growth of tumor cells (PMID: 9428389). Casodex (bicalutamide) is approved, in combination with a luteinizing hormone-releasing hormone (LHRH) analog, for metastatic carcinoma of the prostate (FDA.gov).|
|HSV-Tk||nalotimagene carmaleucel||HSV-Tk is a gene therapy encoding the herpes simplex virus thymidine kinase (HSV-tk), which when introduced together with ganciclovir (GCV), converts GCV to a potent cytotoxic drug that disrupts DNA replication and leads to cell death (PMID: 17327829).|
|Leuprolide||Lupron||Leuprorelin||Lupron (leuprolide) is an agonist of gonadotropin releasing hormone (GnRH), which results decreased testosterone production in males and decreased estradiol production in females, potentially leading to decreased growth of androgen-positive tumors (NCI Drug Dictionary).|
|Valacyclovir||Valtrex||Acicloftal|Virorax|CargosilBW-248U||Valacyclovir is the prodrug of acylovir, which is an antiviral agent that functions by inhibiting viral DNA polymerase (NCI Drug Dictionary).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT03541928||Phase II||Bicalutamide + HSV-Tk + Leuprolide + Valacyclovir||Phase II High Risk Prostate Cancer Trial Using Gene & Androgen Deprivation Therapies, Radiotherapy, & Surgery||Recruiting|